Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy

Citation
Ge. Hanks et al., Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy, CA J SCI AM, 5(3), 1999, pp. 152-158
Citations number
20
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER JOURNAL FROM SCIENTIFIC AMERICAN
ISSN journal
10814442 → ACNP
Volume
5
Issue
3
Year of publication
1999
Pages
152 - 158
Database
ISI
SICI code
1081-4442(199905/06)5:3<152:SAFPCP>2.0.ZU;2-D
Abstract
PURPOSE The value of treating prostate cancer has been questioned, and some insist that a survival benefit is demonstrated to justify treatment. Prospective dose-escalation studies with three-dimensional conformal radiot herapy technique have demonstrated improvement in biochemical freedom from disease and local control. We report the outcomes of high-dose treatment wi th three-dimensional conformal radiotherapy compared with low-dose treatmen t for biochemical freedom from disease, freedom from distant metastasis, ca use-specific survival, and overall survival. PATIENTS AND METHODS The study design was retrospective, involving pairs matched on independent prognostic variables in which each patient treated with low-dose radiothera py was matched with a patient treated with high-dose radiotherapy. Outcomes were compared for two groups of patients: Group I: Three-dimensional conformal radiotherapy treatment-296 patients tr eated with more than 74 Gy matched on stage, grade, and prostate-specific a ntigen level, to 296 patients treated with less than 74 Gy. Group II: Three-dimensional conformal radiotherapy treatment-357 patients t reated with more than 74 Gy matched on stage and grade to 357 patients trea ted with less than 74 Gy. RESULTS Univariate analysis showed that dose is a significant predictor of biochemi cal freedom from disease, freedom from distant metastasis, and cause-specif ic survival for group I and biochemical freedom from disease, freedom from distant metastasis, cause-specific survival, and overall survival for group II. Multivariate analysis showed that dose is a significant independent pr edictor in group I for biochemical freedom from disease and freedom from di stant metastasis and for biochemical freedom from disease, freedom from dis tant metastasis, cause-specific survival, and overall survival in group II. DISCUSSION These data provide strong support for the definitive treatment of prostate cancer with high-dose (> 74 Gy) three-dimensional conformal radiotherapy Th ese doses can be safely delivered with three-dimensional conformal radiothe rapy techniques. Various institutions and industry must collaborate to expand the technology allowing the use of high-dose three-dimensional conformal radiotherapy in the national practice beyond centers of technological excellence.